ES2067250T3 - Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion. - Google Patents

Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion.

Info

Publication number
ES2067250T3
ES2067250T3 ES91917940T ES91917940T ES2067250T3 ES 2067250 T3 ES2067250 T3 ES 2067250T3 ES 91917940 T ES91917940 T ES 91917940T ES 91917940 T ES91917940 T ES 91917940T ES 2067250 T3 ES2067250 T3 ES 2067250T3
Authority
ES
Spain
Prior art keywords
delayed release
solvents
pct
procedure
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91917940T
Other languages
English (en)
Other versions
ES2067250T5 (es
Inventor
Ulrich Munch
Hans-Jurgen Mika
Bernhard Emschermann
Rainer Schmidt
Bernhard Sczepanik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanol Schwarz GmbH
UCB Pharma GmbH
Original Assignee
Sanol Schwarz GmbH
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6415859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2067250(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanol Schwarz GmbH, Schwarz Pharma AG filed Critical Sanol Schwarz GmbH
Application granted granted Critical
Publication of ES2067250T3 publication Critical patent/ES2067250T3/es
Publication of ES2067250T5 publication Critical patent/ES2067250T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

LOS PREPARADOS FARMACEUTICOS DE ADMINISTRACION ORAL, CON LIBERACION RETARDADA DE LAS SUSTANCIAS ACTIVAS, COMPRENDEN UN MATERIAL FUNDIDO GRANULADO Y ENFRIADO, LIBRE DE DISOLVENTES, QUE CONTIENE AL MENOS UNA SUSTANCIA ACTIVA FUNDIBLE, Y AL MENOS UNA SUSTANCIA AUXILIAR FUNDIBLE. EL PREPARADO FARMACEUTICO ES UTILIZABLE EN TODAS LAS FORMAS DE MEDICACION SOLICITADAS Y PARA LA TERAPIA DE ENFERMEDADES.
ES91917940T 1990-10-08 1991-10-07 Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion. Expired - Lifetime ES2067250T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4031881A DE4031881C2 (de) 1990-10-08 1990-10-08 Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung

Publications (2)

Publication Number Publication Date
ES2067250T3 true ES2067250T3 (es) 1995-03-16
ES2067250T5 ES2067250T5 (es) 1999-02-01

Family

ID=6415859

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91917940T Expired - Lifetime ES2067250T5 (es) 1990-10-08 1991-10-07 Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion.

Country Status (24)

Country Link
US (1) US5453283A (es)
EP (1) EP0552227B2 (es)
JP (1) JP3233929B2 (es)
KR (1) KR0166599B1 (es)
AT (1) ATE116843T1 (es)
CA (1) CA2093666C (es)
CZ (1) CZ284923B6 (es)
DE (2) DE4031881C2 (es)
DK (1) DK0552227T4 (es)
ES (1) ES2067250T5 (es)
FI (1) FI108401B (es)
GR (1) GR3015131T3 (es)
HR (1) HRP920960B1 (es)
HU (2) HUT64211A (es)
IE (1) IE76142B1 (es)
LV (1) LV11002B (es)
PL (1) PL167593B1 (es)
PT (1) PT99168B (es)
RU (1) RU2101009C1 (es)
SI (1) SI9111618B (es)
SK (1) SK279446B6 (es)
UA (1) UA26449C2 (es)
WO (1) WO1992005774A1 (es)
YU (1) YU48766B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014421A2 (en) * 1992-12-23 1994-07-07 Saitec S.R.L. Process for preparing controlled release pharmaceutical forms and the forms thus obtained
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4418837A1 (de) * 1994-05-30 1995-12-07 Bayer Ag Thermisches Granulierverfahren
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
MX9707585A (es) * 1995-04-03 1997-12-31 Abbott Lab Mezclas homogeneas de farmacos y aditivos de fusion a baja temperatura para liberacion controlada.
HRP970485A2 (en) 1996-09-13 1998-08-31 Joerg Rosenberg Process for producing solid pharmaceutical forms
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
JP2004521083A (ja) * 2000-10-27 2004-07-15 ニトロメッド，インク． 酸化窒素不足によって特徴づけられる血管疾患の治療方法
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20040029959A1 (en) * 2002-08-08 2004-02-12 John Devane Isosorbide mononitrate compositions and methods of their use
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
NZ561375A (en) 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
KR101659983B1 (ko) 2012-12-31 2016-09-26 주식회사 삼양바이오팜 용융 압출된 방출 제어용 약학 조성물, 및 이를 포함하는 경구용 제제
WO2017086835A1 (ru) * 2015-11-17 2017-05-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты)
AU2018360383A1 (en) 2017-11-02 2020-05-21 Natureceuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297357A (es) * 1962-08-31
US3308217A (en) * 1965-02-09 1967-03-07 Lowy Lawrence Method of granulating materials for subsequent forming into tablets
FI53921C (fi) * 1971-06-04 1978-09-11 Boehringer Mannheim Gmbh Foerfarande foer granulering av tablettmassor i pulverform
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
DE3612211A1 (de) * 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
DE3743947A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur gesteuerten abgabe von nicotin, verfahren zu ihrer herstellung sowie ihre verwendung
DE3743946A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur abgabe von nitroglycerin an die haut, verfahren zu ihrer herstellung sowie ihre verwendung
DE3743945A1 (de) * 1987-09-01 1989-03-09 Lohmann Gmbh & Co Kg Vorrichtung zur abgabe von stoffen, verfahren zu ihrer herstellung sowie ihre verwendung
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5262173A (en) * 1992-03-02 1993-11-16 American Cyanamid Company Pulsatile once-a-day delivery systems for minocycline

Also Published As

Publication number Publication date
DE59104271D1 (de) 1995-02-23
CA2093666C (en) 1998-05-19
PT99168A (pt) 1992-09-30
CA2093666A1 (en) 1992-04-09
FI931576A0 (fi) 1993-04-07
WO1992005774A1 (de) 1992-04-16
IE76142B1 (en) 1997-10-08
SI9111618A (en) 1997-12-31
FI108401B (fi) 2002-01-31
EP0552227A1 (de) 1993-07-28
EP0552227B2 (de) 1998-11-04
LV11002B (en) 1996-06-20
UA26449C2 (uk) 1999-08-30
HU9300995D0 (en) 1993-07-28
DE4031881A1 (de) 1992-04-09
HUT64211A (en) 1993-12-28
ATE116843T1 (de) 1995-01-15
GR3015131T3 (en) 1995-05-31
HRP920960B1 (en) 1998-10-31
ES2067250T5 (es) 1999-02-01
RU2101009C1 (ru) 1998-01-10
JP3233929B2 (ja) 2001-12-04
YU48766B (sh) 1999-12-27
HRP920960A2 (en) 1995-08-31
EP0552227B1 (de) 1995-01-11
FI931576A (fi) 1993-04-07
DE4031881C2 (de) 1994-02-24
KR930701963A (ko) 1993-09-08
JPH06501685A (ja) 1994-02-24
DK0552227T3 (da) 1995-03-27
PL167593B1 (pl) 1995-09-30
KR0166599B1 (ko) 1999-01-15
SK279446B6 (sk) 1998-11-04
CS305091A3 (en) 1992-04-15
YU161891A (sh) 1994-06-10
DK0552227T4 (da) 1999-07-19
HU211845A9 (en) 1995-12-28
PT99168B (pt) 1999-04-30
IE913592A1 (en) 1992-04-08
SI9111618B (sl) 1999-08-31
US5453283A (en) 1995-09-26
CZ284923B6 (cs) 1999-04-14
LV11002A (lv) 1996-02-20

Similar Documents

Publication Publication Date Title
ES2067250T3 (es) Preparado farmaceutico sin disolventes para administracion oral, con liberacion retardada de la sustancia activa y procedimiento para su fabricacion.
MX9200180A (es) DERIVADOS DE LA 5H-PIRROL (3,4-b) PIRAZINA OPTICAMENTE ACTIVOS, PROCEDIMIENTO PARA SU PREPARACION Y COMPOSICION FARMACEUTICA QUE LOS CONTIENE.
NO870558D0 (no) Fremgangsmaate for fremstilling av et langsomt frigivende farmasoeytisk preparat.
DE69011059D1 (de) Heterozyklische Acylaminothiazolderivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen.
ES2109377T3 (es) Proceso para la preparacion de una dispersion solida.
KR0173989B1 (en) Preparation of pharmaceutical and other matrix systems by solid-state dissolution
ATE128863T1 (de) Arzneimittelformulierungen mit verzögerter wirkstoffabgabe.
RU93036959A (ru) Свободно растворимый лекарственный препарат с замедленным действием биологически активных веществ, назначенный для приема внутрь, способ его производства
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
TW223592B (es)
DE3852145D1 (de) Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
YU242589A (en) New substituted benzimidazole and process for obtaining thereof
NO985145L (no) Farmas°ytiske preparater for forsinket frigj°ring av uoppl°selige, aktive bestanddeler
NO870104D0 (no) Farmasoeytisk preparat med vedvarende frigivelse av den aktive komponenten og fremgangsmaate for fremstilling derav.
SE9604752D0 (sv) Formulation and use
NO160258C (no) Analogifremgangsmaate for fremstilling av farmakologisk aktive pyridazinonimin-derivater.
JO1653B1 (en) The current benzimidazole is a therapeutically active method for preparing it
JPS57203008A (en) Novel suppository
ITBO920455A1 (it) Procedimento per preparare forme farmaceutiche a rilascio controllato ritardato del principio attivo e le forme farmaceutiche cosi' ottenute.
IT8819182A0 (it) Derivati dell'ambroxol,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552227

Country of ref document: ES